[{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"MEXICO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Instituto Mexicano del Seguro Social","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Silanes \/ Instituto Mexicano del Seguro Social","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Silanes \/ Instituto Mexicano del Seguro Social"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Instituto Mexicano del Seguro Social","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Silanes \/ Instituto Mexicano del Seguro Social","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Silanes \/ Instituto Mexicano del Seguro Social"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akums Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Macleods Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Macleods Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Bilayer","sponsorNew":"Exemed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Mascot Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Undisclosed"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Mascot Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"HANDOK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HANDOK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HANDOK \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Emcure Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Glimepiride","moa":"SUR-1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Emcure Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Pharmaceutical Research Unit, Jordan","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JORDAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmaceutical Research Unit, Jordan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaceutical Research Unit, Jordan \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaceutical Research Unit, Jordan \/ Sanofi"},{"orgOrder":0,"company":"Harsen Laboratories","sponsor":"Pharma Metric Labs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Harsen Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harsen Laboratories \/ Pharma Metric Labs","highestDevelopmentStatusID":"1","companyTruncated":"Harsen Laboratories \/ Pharma Metric Labs"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Juvenile Diabetes Research Foundation | Amylin Pharmaceuticals | Eli Lilly | Johnson & Johnson | Merck & Co | Novartis Pharmaceuticals Corporation | Pfizer Inc | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ National Institute of Diabetes and Digestive and Kidney Diseases | Juvenile Diabetes Research Foundation | Amylin Pharmaceuticals | Eli Lilly | Johnson & Johnson | Merck & Co | Novartis Pharmaceuticals Corporation | Pfizer Inc | Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ National Institute of Diabetes and Digestive and Kidney Diseases | Juvenile Diabetes Research Foundation | Amylin Pharmaceuticals | Eli Lilly | Johnson & Johnson | Merck & Co | Novartis Pharmaceuticals Corporation | Pfizer Inc | Takeda Pharmaceutical"},{"orgOrder":0,"company":"GRADE Study Group","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | National Heart, Lung, and Blood Institute | Becton Dickinson | Bristol Myers Squibb | Merck & Co | Novo Nordisk | F. Hoffmann-La Roche | Sanofi | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase III","graph3":"GRADE Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRADE Study Group \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Heart, Lung, and Blood Institute | Becton Dickinson | Bristol Myers Squibb | Merck & Co | Novo Nordisk | F. Hoffmann-La Roche | Sanofi | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"GRADE Study Group \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Heart, Lung, and Blood Institute | Becton Dickinson | Bristol Myers Squibb | Merck & Co | Novo Nordisk | F. Hoffmann-La Roche | Sanofi | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Diabetes Frail","sponsor":"Merck & Co | University of Campania Luigi Vanvitelli","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glimepiride","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diabetes Frail","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diabetes Frail \/ Merck & Co | University of Campania Luigi Vanvitelli","highestDevelopmentStatusID":"10","companyTruncated":"Diabetes Frail \/ Merck & Co | University of Campania Luigi Vanvitelli"}]
Find Clinical Drug Pipeline Developments & Deals for Glymepirid
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
